focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.50
Ask: 4.50
Change: 0.49 (13.96%)
Spread: 1.00 (28.571%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Totally slides again; Proteome warns on earnings

Thu, 30th Nov 2023 11:04

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Ashtead Technology Holdings PLC, up 20% at 582.00 pence, 12-month range 281.00p-594.00p. The subsea equipment rental, serving the offshore energy sector, says it now expects 2023 results to be "comfortably ahead of its previous expectations". It also announces a GBP53.5 million deal to acquire ACE Winches, from that firm's founders Alfie and Valerie Cheyne. ACE offers lifting, pulling and deployment services, and will sit nicely with "Ashtead Technology's existing equipment and services portfolio", it says.

----------

AIM - LOSERS

----------

Proteome Sciences PLC, down 25% at 4.54p, 12-month range 3.15p-8.79p. The protein-focused drug development services provider cuts its revenue outlook for 2023 amid delays to projects. It expects its top line to shrink from 2022's GBP7.8 million. "As reported by many other life science technology providers, the company has experienced delays to projects, many of which have been postponed to 2024. The healthcare industry has faced a very challenging market environment this year, especially in the second half of the year," Proteome Sciences explains. Proteome adds that reduced revenue combined with its commitment to invest in a US lab, means its now expects to post a net loss for 2023. In 2022, the company posted a profit after tax of GBP1.3 million. Proteome says it expects its US laboratory to be operational in the coming weeks and is lining up first customer projects for this laboratory.

----------

Totally PLC, down 16% at 4.85p, 12-month range 4.80p-38.00p. A poor week for the stock continues and it looks likely to suffer a fourth-successive share price decline. On Tuesday, the healthcare services provider in UK and Ireland reported that it swung to a pretax loss of GBP1.9 million in the first half ended September 30, from a profit of GBP1.0 million the year prior. Revenue fell 21% to GBP55.8 million during the period, from GBP70.3 million a year ago, Totally said. The firm blamed a "crisis" faced by the UK NHS for the lower revenue, given the loss of its North West London contracts. Shares have fallen 48% so far this week and it hit this 12-month low on Thursday.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Nov 2013 07:52

AIM IN BRIEF: Rangers FC Appoints Graham Wallace As CEO

Read more
30 Sep 2013 09:26

Proteome Sciences Losses Widen Despite Revenue Growth; Signs USD2.1M Contract

Read more
18 Sep 2013 15:03

Proteome Expects Strong Second-Half Growth After Making Alzheimer's Progress

Read more
12 Jun 2013 11:37

Proteome Sciences to develop cancer pathway profiling assays

AIM-listed biotech group Proteome Sciences has unveiled its largest contract to date comprising a technology agreement with Thermo Fisher Scientific, to develop advanced methods to profile changes in cancer pathways. Proteome Sciences said that the contract - which it valued at £2.1m - would prov

Read more
18 Mar 2013 14:29

Proteome Sciences looks ahead with confidence

Drug developer Proteome Sciences has told investors that it expects strong revenue growth across the company's three main divisions in 2013 and said it is 'much encouraged by the prospects'. The announcement comes after the group received a positive response to the presentation of four posters tha

Read more
31 Dec 2012 12:50

STOCKS NEWS EUROPE-UK small caps closes modestly higher

The FTSE Small Caps index closes 0.1 percent higher on Monday, New Year's Eve, tracking similar modest gains by the mid caps, also up 0.1 percent, while the blue chips shed 0.5 percent after a half-day session. The small caps index has gained 24 percent over 2012, just outperforming a 22 percent adv

Read more
31 Dec 2012 10:48

Proteome delivers encouraging results from Alzheimers study

Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function. The firm said the results provide important in-vivo proof of prin

Read more
28 Sep 2012 10:46

Proteome Sciences narrows losses, bright outlook

Proteomics specialist Proteome Sciences reduced half year losses and expects second half revenues to be significantly boosted as it doubles the number of biomarker tests available from PS Biomarker Services. The group expects major licences and contracts from its proprietary biomarkers and services

Read more
18 Sep 2012 10:57

Proteome stroke test could save thousands from brain damage

Medical technology group Proteome Sciences has released details of a study into a blood test which could reduce brain damage in thousands of stroke victims. The group has been collaborating with researchers at the University of Geneva to produce the test which can tell how long ago a stroke actuall

Read more
20 Aug 2012 07:43

London pre-open: Doubts about further Chinese stimulus

City sources predict the FTSE 100 will open up five points from Friday's close of 5,852, having gained 18 points during Friday's session following positive data from the US. Over the weekend it was reported in Europe by the Handelsblatt newspaper that the European Union could appoint the European

Read more
20 Aug 2012 07:20

Proteome Sciences reports collaboration research agreement

Biotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility

Read more
5 Apr 2012 11:50

Proteome issues new licence for stroke product

Pharma group Proteome Sciences has granted a non-exclusive licence to UK firm Randox Laboratories for its portfolio of stroke biomarkers. Under the terms of the agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Proteome will ear

Read more
28 Mar 2012 10:46

Proteome rockets on Alzheimer's blood test

Pharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease. A study of 1,000 patients has shown three distinct "biomarkers" in people's blood which can discriminate between mild "cognitive

Read more
19 Mar 2012 10:17

Stroke consortium to get €11m grant

Shares in biomarker specialist Proteome Sciences rose almost 5% on Monday morning after it announced the EU was to award €11m to a consortium of which it is a member. Euro-HYP-1, a consortium of academic, clinical and industrial European partners that includes Proteome, has been awarded the grant f

Read more
27 May 2011 12:09

Proteome boosted by Sanofi settlement

Biomarker specialist Proteome Sciences is back in profit after receiving €11m from Sanofi-Aventis to settle a warranty claim. The company posted pre-tax profits of £4.59m in the year to the end of December, including the warranty claim. This compared £4.20m pre-tax loss in 2009. Revenues for 2010

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.